Core Insights - Perimeter Solutions, Inc. (PRM) has announced a $550 million offering of 6.250% senior secured notes due January 15, 2034, with an expected closing date of January 2, 2026 [1][8] Group 1: Offering Details - The notes will mature on January 15, 2034, and will bear interest at a rate of 6.250% per annum, payable semi-annually [1] - The offering is fully guaranteed on a senior secured basis by Perimeter Intermediate, LLC, and secured by first-priority interests on substantially all present and future assets of Perimeter Holdings and its guarantors [2][8] Group 2: Use of Proceeds - The net proceeds from the offering, along with cash on hand, will be used to fund the acquisition of Medical Manufacturing Technologies LLC (MMT) and to cover related fees and expenses [3][8] - If the acquisition is not completed by September 9, 2026, or if the company decides not to pursue it, Perimeter Holdings will be required to redeem the notes [3] Group 3: Strategic Implications - The acquisition of MMT is expected to enhance Perimeter's focus on businesses in secular growth markets characterized by strong free cash flow, high returns on tangible capital, and sustainable earnings power [4] - Post-transaction, the company anticipates a net leverage ratio of approximately 2.7x net debt to combined adjusted EBITDA for the last 12 months ending September 30, 2025 [4] Group 4: Market Performance - PRM shares have increased by 117.3% over the past year, contrasting with a 1% decline in the industry [6]

Key Takeaways The chemical industry faced weak demand in construction, autos and electronics amid inflation and tariffs.Soft demand in China and Europe, plus trade tariffs, continued to pressure chemical volumes in 2025.Chemical makers are cutting costs and improving efficiency to protect margins heading into 2026.The chemical industry has grappled with a demand slowdown in certain major markets, including consumer durables and building & construction, cautious spending by customers and pockets of inventory ...

CLAYTON, Miss., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Perimeter Solutions, Inc. (NYSE: PRM) (“Perimeter,” “Perimeter Solutions,” or the “Company”), today announced that its indirect subsidiary, Perimeter Holdings, LLC (“Perimeter Holdings”) priced an offering of $550 million aggregate principal amount of 6.250% senior secured notes due 2034 (the “Notes”). The Notes will bear interest at 6.250% per year, payable semi-annually, will mature on January 15, 2034. The Notes will be fully and unconditionally guarantee ...

Have you been paying attention to shares of Perimeter Solutions, SA (PRM) ? Shares have been on the move with the stock up 12.2% over the past month. The stock hit a new 52-week high of $29.78 in the previous session. Perimeter Solutions, SA has gained 122.3% since the start of the year compared to the 28.6% move for the Zacks Basic Materials sector and the -1.8% return for the Zacks Chemical - Specialty industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surpr ...

Core Viewpoint - Perimeter Solutions, Inc. plans to offer $550 million in senior secured notes to finance the acquisition of Medical Manufacturing Technologies LLC and related expenses [1][2]. Group 1: Offering Details - Perimeter Holdings intends to issue $550 million in senior secured notes due in 2034, guaranteed by Perimeter Intermediate and certain subsidiaries [1]. - The notes will be secured by a first-priority security interest in substantially all assets of Perimeter Holdings and the guarantors [1]. Group 2: Use of Proceeds - The net proceeds from the notes offering, along with cash on hand, will be used to pay for the acquisition of MMT and associated fees [2]. Group 3: Conditions and Obligations - If the acquisition of MMT is not completed by September 9, 2026, or if Perimeter Holdings decides not to pursue the acquisition, it will be required to redeem the notes [3]. Group 4: Credit Facility Amendments - Prior to the notes offering, Perimeter Holdings plans to amend its existing revolving credit facility to increase the principal amount to up to $200 million and extend the maturity date [4].

Key Takeaways PRM agreed to acquire MMT for about $685M in an all-cash deal expected to close by early 2026.The purchase adds MMT's machinery and consumables business, which is set to earn $140M in revenues in 2025.PRM plans to fund the deal with debt and cash, expecting net leverage of roughly 2.7x after closing.Perimeter Solutions, Inc. (PRM) announced a definitive agreement to acquire Medical Manufacturing Technologies LLC (“MMT”) from Arcline Investment Management for roughly $685 million. PRM will buy ...

Core Viewpoint - Perimeter Solutions has announced the acquisition of Medical Manufacturing Technologies, LLC (MMT), indicating a strategic move to enhance its capabilities in the market [2]. Group 1: Acquisition Details - The acquisition of MMT is a significant step for Perimeter Solutions, aimed at expanding its operational scope and product offerings [2]. - The company is expected to discuss the implications of this acquisition during the conference call [2]. Group 2: Financial Information - The call will reference non-GAAP financial measures, including adjusted EBITDA, with further details available in the press release and investor presentation [4].

Summary of Perimeter Solutions Conference Call on M&A Announcement Company and Industry - **Company**: Perimeter Solutions (NYSE: PRM) - **Acquisition Target**: Medical Manufacturing Technologies LLC (MMT) - **Industry**: Medical Device Manufacturing Core Points and Arguments 1. **Acquisition Details**: Perimeter Solutions is acquiring MMT for $685 million in cash, which includes certain tax benefits. MMT is a leader in precision machinery for minimally invasive medical devices, expected to generate approximately $140 million in revenue and $50 million in EBITDA in 2025 [4][12][10]. 2. **Funding Structure**: The acquisition will be funded through $500 million of new senior secured debt financing and approximately $185 million of cash on hand. Post-acquisition, total debt is expected to be around $1.2 billion, with net debt just over $1 billion [4][12][13]. 3. **Operational Fit**: MMT aligns with Perimeter's operational pillars, focusing on high-quality industrial businesses, value driver operating strategy, and a decentralized structure. MMT's strong margins and growth potential are highlighted [5][6][8]. 4. **Market Trends**: The growth of MMT is driven by increasing adoption of minimally invasive procedures, device complexity, and machinery outsourcing. The installed base of MMT has grown at a CAGR of approximately 5% since 2016 [11][10]. 5. **Aftermarket Revenue**: Approximately 50% of MMT's revenue comes from aftermarket consumables and services, which are critical for customer compliance and quality management systems [10][11]. 6. **Regulatory Compliance**: MMT's products are specified in regulatory filings with the FDA, creating a competitive moat around the business [17][10]. 7. **Future Growth Opportunities**: There is potential for further acquisitions to broaden MMT's product suite, with a focus on tuck-in M&A to enhance customer offerings [26][28]. Additional Important Content 1. **Financial Metrics**: The acquisition price implies a purchase price multiple of approximately 14 times Adjusted EBITDA, which is considered attractive given the expected growth [12]. 2. **Capital Intensity**: MMT is expected to fit into Perimeter's relatively low capital intensity model, requiring only a few million dollars of CapEx against the projected $50 million of EBITDA [16]. 3. **Customer Relationships**: MMT has long-standing relationships with top customers, averaging 15 years, which enhances customer loyalty and revenue stability [10]. 4. **Decentralized Management**: MMT will operate as a standalone business within Perimeter's decentralized structure, allowing for operational autonomy and accountability [7][5]. 5. **Market Stability**: The end market for MMT's products is relatively steady, driven by the number of medical procedures, which supports long-term growth [24]. This summary encapsulates the key points discussed during the conference call regarding Perimeter Solutions' acquisition of MMT, highlighting the strategic fit, financial implications, and market dynamics.

Perimeter Solutions MMT Acquisition Call December 11, 2025 Disclaimer Certain statements in this presentation and discussion are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on Perimeter Solutions, Inc.'s (the "Company") expectations, intentions and projections regarding the Company's future performance, anticipated events or trends and other matters that are not historical facts. Words such as "anticipate," "estimate," "seek," "expect," ...

Core Viewpoint - Arcline Investment Management has agreed to sell its portfolio company Medical Manufacturing Technologies to Perimeter Solutions for $685 million, marking a significant transaction in the medical device manufacturing sector [1][4]. Company Overview - Medical Manufacturing Technologies (MMT), based in Charlotte, North Carolina, is a leading global provider of medical device manufacturing solutions, serving over 1,000 customers, including major medical technology OEMs and CDMOs [2]. - MMT specializes in the production of complex interventional medical devices such as catheters, guidewires, stents, and microcoils, operating with over 350 employees across 14 production facilities [2]. Investment Strategy - Since acquiring MMT in 2020, Arcline has implemented a disciplined strategy to enhance the company's capabilities, resulting in significant revenue and EBITDA growth, alongside 13 targeted acquisitions that expanded MMT's offerings in automation and specialty manufacturing [3]. - The strategy focused on building a scaled provider of mission-critical manufacturing technologies for medical device OEMs and CDMOs [3]. Transaction Details - The transaction is anticipated to close in the first quarter of 2026, pending regulatory approvals and customary closing conditions [4]. - Financial advisors for the transaction include William Blair and Houlihan Lokey, while legal advisors are Kirkland & Ellis LLP and Fredrikson & Byron P.A. [4].